ResMed (RMD)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$219.77+0.63%
Close 2026-07-07 · 1-day change
Reading RMD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track RMD free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading RMD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track RMD free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on innovation and digital health. The current thesis state is intact, supported by strong recent financial performance and management's commitment to growth initiatives.
The market appears to have priced in a neutral valuation, with RMD being seen as cheap compared to peers. There is a slight expectations gap, indicating that the market may not fully account for potential upside from continued sector momentum.
Fundamentals are likely to remain stable, as management is on track with its priorities, including maintaining gross margins and investing in innovation. However, there is a moderate risk due to the company's history of misses, which could impact future performance.
The thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. If these companies continue to perform well, it could support RMD's growth. Conversely, any negative guidance from these peers could adversely affect RMD's outlook.
Overall, RMD's long-term thesis remains intact, supported by solid fundamentals and sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read, indicating strong recent performance. However, concerns about maintaining gross margin guidance pose a threat to the outlook.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Revenue growth reflects demand for ResMed's products. A slowdown could indicate market challenges.
Confirms:Next earnings report shows revenue growth of at least 10% year over year.
Disproves:Revenue growth is under 8% year over year. This suggests possible demand problems.
Why it matters: Keeping gross margin guidance is important. It helps build trust with investors.
Confirms:Gross margin reported at 62% or higher in the next earnings report.
Disproves:Gross margin reported below 62% in the next earnings report.
Why it matters: The new CFO's plans can impact financial management and growth strategies. Investors will want to see how this affects ResMed's direction.
Confirms one read:A press release will explain the new CFO's plans in three months.
Confirms the other:No clear strategy or direction outlined by the new CFO within three months.
Why it matters: The new CFO, Aaron Bloomer, may shift financial strategies that could affect growth and margins.
Confirms one read:Look for good financial results next quarter. Revenue growth above 10% is a sign.
Confirms the other:Financial performance metrics decline, with revenue growth below 5% in the next quarter.
Why it matters: Strong revenue growth in digital health shows successful new ideas and market interest.
Confirms:Revenue growth from digital health products exceeds 15% year over year in the next report.
Disproves:Revenue growth from digital health products is below 5% year over year in the next report.
Why it matters: A slowdown in sector growth could affect ResMed's performance. It signals broader market challenges.
Confirms:Sector revenue growth drops below its median level.
Disproves:Sector revenue growth is still higher than average. This shows strong performance.
Why it matters: Investing in innovation is crucial for growth. Increased spending signals confidence in future growth.
Confirms:Announcement of new product launches or increased R&D spending.
Disproves:No new product announcements or cuts to R&D budgets.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: New products can drive growth and market share. Delays or failures could hurt future earnings.
Confirms:The new AI-powered medical device is popular. It sells very well.
Disproves:Sales are low or feedback on the new product is bad. This shows market resistance.
Why it matters: The new CFO, Aaron Bloomer, may change financial strategies. This could affect growth and margins.
Confirms one read:ResMed shows better financial results under Aaron Bloomer's leadership. This includes higher gross margins and revenue growth.
Confirms the other:Financial results drop or do not meet past goals. This shows a negative effect from the transition.
Why it matters: Investing in innovation is crucial for growth. Updates can show how ResMed is adapting to market needs.
Confirms:Announcement of a new digital health product or service launch within six months.
Disproves:No new product or service announcements in digital health within six months.